COMPASS Pathways (NASDAQ:CMPS) Announces Quarterly Earnings Results

by · The Markets Daily

COMPASS Pathways (NASDAQ:CMPS – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04, Zacks reports. During the same quarter last year, the business earned ($0.67) earnings per share.

COMPASS Pathways Price Performance

CMPS stock traded down $0.01 during midday trading on Friday, hitting $4.75. 2,081,860 shares of the stock were exchanged, compared to its average volume of 874,967. The stock’s 50-day moving average price is $6.61 and its 200-day moving average price is $7.04. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03. The stock has a market cap of $324.85 million, a price-to-earnings ratio of -2.16 and a beta of 2.29. COMPASS Pathways has a fifty-two week low of $4.05 and a fifty-two week high of $12.75.

Insider Buying and Selling at COMPASS Pathways

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now owns 6,905,774 shares in the company, valued at $41,779,932.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.25% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CMPS has been the topic of several analyst reports. Maxim Group lowered their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Royal Bank of Canada reduced their price target on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday. HC Wainwright dropped their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday. Finally, Canaccord Genuity Group reduced their target price on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $30.67.

Check Out Our Latest Stock Analysis on COMPASS Pathways

COMPASS Pathways Company Profile

(Get Free Report)

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Read More